Journal of Cardiology (2011) 57, 18—30
available at www.sciencedirect.com
journal homepage: www.elsevier.com/locate/jjcc
Review
Recent advances in coronary angioscopy
Yasumi Uchida (MD) ∗
Japan Foundation for Cardiovascular Research, 2-30-17, Narashinodai, Funabashi, Japan
Received 27 October 2010; accepted 29 October 2010
Available online 10 December 2010
KEYWORDS
Vulnerable coronary
plaques;
Conventional
angioscopy;
Dye-staining
angioscopy;
Near-infrared
fluorescence
angioscopy;
Color fluorescence
angioscopy
Summary Angioscopy enables macroscopic pathological diagnosis of cardiovascular diseases
from the inside. This imaging modality has been intensively directed to characterizing vulnerable coronary plaques. Scoring of plaque color was developed, and based on prospective
studies; dark yellow or glistening yellow plaques were proposed as vulnerable ones. Colorimetry apparatus was developed to assess the yellow color of the plaques quantitatively. The
effects of lipid-lowering therapies on coronary plaques were confirmed by angioscopy. However,
since observation is limited to surface color and morphology, pitfalls of this imaging technology became evident. Dye-staining angioscopy and near-infrared fluorescence angioscopy were
developed for molecular imaging, and the latter method was successfully applied to patients.
Color fluorescence angioscopy was also established for molecular and chemical basis characterization of vulnerable coronary plaques in both in vitro and in vivo. Drug-eluting stents (DES)
reduce coronary restenosis significantly, however, late stent thrombosis (LST) occurs, which
requires long-term antiplatelet therapy. Angioscopic grading of neointimal coverage of coronary stent struts was established, and it was revealed that neointimal formation is incomplete
and prevalence of LST is higher in DES when compared to bare-metal stent. Many new stents
were devised and they are now under experimental or clinical investigations to overcome the
shortcomings of the stents that have been employed clinically. Endothelial cells are highly antithrombotic. Neoendothelial cell damage is considered to be caused by friction between the cells
and stent struts due to the thin neointima between them that might act as a cushion. Therefore,
development of a DES that causes an appropriate thickness (around 100 m) of the neointima is
a potential option with which to prevent neoendothelial cell damage and consequent LST while
preventing restenosis.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Contents
Introduction...............................................................................................................
Developmental history of coronary angioscopy ............................................................................
Vulnerable coronary plaques ..............................................................................................
∗
Tel.: +81 47 462 2159; fax: +81 47 462 2159.
E-mail address: uchiy@ta2.so-net.ne.jp
0914-5087/$ — see front matter © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.jjcc.2010.11.001
19
19
20
Recent advances in coronary angioscopy
19
Detection of vulnerable coronary plaques by angioscopy .............................................................
Classification of plaque color .........................................................................................
Quantitative analysis of plaque color .................................................................................
Angioscopic identification of vulnerable plaques by surface color.....................................................
Prediction of acute coronary syndromes by angioscopy ...............................................................
Relations of angioscopic images to those by intravascular ultrasonography (IVUS), optical coherence tomography
(OCT) and computed tomography (CT)................................................................................
Pitfalls of angioscopy in detecting vulnerable plaques ................................................................
A vulnerable coronary plaque has a thin fibrous cap with a large lipid core beneath: A fact or story? .................
Pre-stage of erosion ..................................................................................................
Acute coronary syndromes without obvious coronary plaque disruption ...............................................
Detection of vulnerable coronary plaques by new imaging modalities.................................................
Detection of vulnerable coronary plaques by near-infrared spectroscopy .............................................
Detection of vulnerable coronary plaques by near-infrared fluorescence angioscopy..................................
Detection of vulnerable coronary plaques by color fluorescence angioscopy ..........................................
Evaluation of progressiveness toward vulnerable plaques .............................................................
Oxidized low-density lipoprotein imaging ......................................................................
Lysophosphatidylcholine imaging...............................................................................
Cholesterol and cholesteryl ester imaging .....................................................................
Macrophage imaging ......................................................................................
Evaluation of stabilization and regression of vulnerable plaques by angioscopy ...........................
Lipid-lowering therapy.........................................................................................
Molecular or cellular targeting therapy ...................................................................
Evaluation of neointimal coverage of coronary stents by angioscopy ......................................
Grading of neointimal coverage by angioscopy .................................................................
Difference in neointimal coverage between bare-metal and drug-eluting stents ...............................
Late-stent thrombosis.....................................................................................
Possible mechanisms of late-stent thrombosis and appropriate neointimal thickening to prevent restenosis, and
neoendothelial cell damages and consequent late-stent thrombosis ..................................................
Conclusion............................................................................................................
References ...........................................................................................................
20
20
20
21
21
21
21
22
22
22
22
23
23
23
23
23
23
24
24
24
24
25
25
25
25
25
26
28
29
Introduction
Developmental history of coronary angioscopy
Angioscopy enables macroscopic pathological diagnosis of
cardiovascular diseases from the inside. This imaging
modality has been intensively directed to characterizing
vulnerable coronary plaques. Scoring of plaque color was
developed, and based on prospective studies, dark yellow or
glistening yellow plaques were proposed as vulnerable ones.
Colorimetry apparatus was developed to assess the yellow
color of the plaques quantitatively.
The effects of lipid-lowering therapies on coronary
plaques were confirmed by angioscopy. However, since
observation is limited to surface color and morphology, pitfalls of this imaging technology became evident.
Dye-staining angioscopy and near-infrared fluorescence
angioscopy were developed for molecular imaging, and the
latter method was successfully applied to patients. Color
fluorescence angioscopy was also established for molecular
and chemical basis characterization of vulnerable coronary
plaques in both in vitro and in vivo.
Drug-eluting stents (DES) reduce coronary restenosis significantly, however, late stent thrombosis (LST) occurs,
which requires long-term antiplatelet therapy. Mechanisms
of LST were clarified considerably by angioscopy.
This article describes the past and present status of coronary angioscopy.
On August 31, 1945, a big storm hit the Kanto district of
Japan. Trains were stopped for several hours due to the
storm and Tsutomu Uji, a surgeon from Tokyo University and
Masanao Sugiura of Olympus Company happened to meet
in the train. A concept of new endoscope was discussed,
which could be the start of the development of endoscopy
in Japan.
In December 1949, in collaboration with Masao Fukaomi
and Minoru Maruyama, they developed a flexible gastroscope
12 mm in diameter with films and illumination source in the
distal most tip. Anesthetized dogs were successfully examined with this endoscope.
Takeshi Sakamoto used this endoscope for the first time
as a gastroscope. A flexible gastroscope thus developed
has provided the basic structure for bronchoscopes, cystoscopes, etc.
Several years later, this gastroscope was replaced by a
fiberscope which was more flexible and more easy to be
manipulated. Fiberscopes have been widely applied to diagnosis and treatment not only of digestive tracts but also
respiratory and urogenital tracts as an essential tool.
Although an endoscope was clinically applied to the heart
during surgery by Allen in 1922 [1], many years elapsed
until percutaneous transluminal coronary angioscopy was
20
Y. Uchida
Figure 1 Angioscopic images of a coronary plaque before and after disruption. A 60-year-old male. A glistening yellow plaque in
the proximal segment of the right coronary artery before (black arrow in A) and disruption of the identical plaque (black arrow in
B) and thrombus formation (white arrow in B) observed 3-h after the onset of acute coronary syndrome.
Reproduced from Uchida et al. [15], with permission.
performed. This was due to the difficulty in the displacement of blood in the artery and the need for more flexible
and thinner endoscope.
With anticipation for clinical application, we (the author
and employees of Olympus Co) began to develop a new fiberscope for coronary use in 1976 Thrombosis and thrombolysis
in the removed human coronary artery and the changes
induced by balloon angioplasty were successfully observed
by this endoscope in 1986 [2].
Meanwhile, Spears observed coronary ostia by the use
of a broncoscope [3]. Also, coronary arterial changes were
observed mainly intraoperatively by Litvack [4].
Using fiberscopes specially designed for coronary use,
the author observed percutaneously from proximal to distal
coronary segments in patients with ischemic heart disease (1984, 1987) [5]. Observation of plaque disruption
and thrombi in acute coronary syndromes (ACS) was performed by Hoeler [6]. Evaluation of coronary interventions
by POBA was performed by the author (1989) [7,8]. Coronary
intervention by laser was evaluated by the author (1987),
Nakamura [9], and evaluation of coronary interventions by
stent by Ueda [10]. Stent and cutting balloon were studied
by many investigators. Application of percutaneous coronary
angioscopy was extended to diagnosis of Kawasaki disease by
Ishikawa [11].
Thus, percutaneous angioscopy is now routinely performed for examinations of underlying mechanisms
of ACS [12], for selection of therapeutic modalities, for evaluation of medical [13], interventional
[14], and surgical therapies and for prediction of ACS
[15].
Vulnerable coronary plaques
It is still not predictable, in whom, when, where and during
what she (he) is doing, ACS occur. If they become predictable, it is a great gospel for mankind. Many workers have
devoted time to characterize vulnerable coronary plaques
that trigger these fatal syndromes. However, characterization of vulnerable coronary plaques is still not established.
Vulnerabilty has two aspects of meaning; one is the fragile plaques that are easily disrupted by mechanical stimuli
and another is the plaques rapidly progressing toward fragile ones by inflammatory or metabolic processes. In clinical
situations, the former are usually considered as vulnerable
ones.
Detection of vulnerable coronary plaques by
angioscopy
Angioscopy has contributed to understanding the underlying
mechanisms of ACS.
It was found that thrombus formation on the disrupted
yellow coronary plaques is the typical causative mechanism
of ACS in the majority of patients [4]. Therefore, a certain
group of yellow plaques has been considered as vulnerable
to disruption.
Fig. 1 demonstrates angioscopic images of a yellow
plaque before and immediately after the onset of ACS (STelevation myocardial infarction). Disruption of the identical
plaque and thrombus formation on it were evident after the
onset of attack [15].
Classification of plaque color
Scoring of vulnerability by surface color was made; namely
white, light yellow, yellow, and dark yellow as 0, 1, 2, and
3 respectively; or white, light yellow, yellow, and glistening yellow plaques as 0, 1, 2, and 3, respectively [16—18]
(Fig. 2).
Since dark yellow and glistening yellow plaques often
have thin fibrous cap with lipid pool beneath by histology,
intravascular ultrasonography (IVUS) or optical coherence
tomography (OCT), they are proposed as vulnerable ones.
Quantitative analysis of plaque color
Angioscopic color assessment of plaques is influenced by
light irradiated onto them. Furthermore, yellow color
Recent advances in coronary angioscopy
21
Figure 2 Angioscopic classification of coronary plaques. From A to E: white, light yellow, yellow, dark yellow, and glistening
yellow plaques, respectively.
grading is often different from observer to observer. Therefore, intra- and interobserver observation system has been
employed for color grading.
In order to avoid this rather subjective grading, a quantitative color analysis was attempted. Ishibashi et al. and
Okada et al. developed a colorimetry apparatus for quantitative assessment of yellow color of the plaques, and they
found that the plaques with high yellow color are vulnerable
to thrombosis [19,20].
Angioscopic identification of vulnerable plaques by
surface color
Although scoring of vulnerabilty by depth of yellow color
is one approach for characterization of vulnerable plaques,
relationships between depth of yellow color and histological vulnerability remain unclear. It was reported that yellow
color of human coronary plaques is determined by deposition
of -carotene, and in addition to its concentration, its deposition with cholesteryl esters increases depth of yellow color
[21]. Therefore, relationships between histological changes
and molecular imaging of lipids should be examined for more
specific diagnosis of vulnerable coronary plaques.
Since angioscopic observation is limited to surface color
and morphology, the histological and molecular changes
inside the plaque are beyond the scope of this imaging technology.
Prediction of acute coronary syndromes by
angioscopy
It was reported that the glistening yellow plaques are prone
to disrupt and ACS more frequently develop in patients having this type of plaque and the changes in the identical
plaques before and immediately after onset of ACS were
observed by angioscopy. It was revealed that ACS developed
in 3.3% of white plaque group, 7.6% of non-glistening yellow
plaque group, and 68.4% of glistening yellow plaque group
[15].
Ohtani et al. followed up 552 patients by angioscopy for
57.3 months. ACS events occurred in 7.1%. Patients with
number of yellow plaques ≥2 and ≥5 had 2.2 and 3.8-fold
higher event rates, respectively than those with number of
yellow plaques 0 or 1 [22].
Relations of angioscopic images to those by
intravascular ultrasonography (IVUS), optical
coherence tomography (OCT) and computed
tomography (CT)
Coronary plaques were analyzed by angioscopy and OCT in
combination by Takano et al. They observed an inverse relation between color grade and fibrous cap thickness [23].
Komatsu et al. classified coronary plaques by multi-detector
row computed tomography into soft, intermediate, and calcified plaques, and he found good correlation between soft
plaque and angioscopic yellow plaque [24].
Pitfalls of angioscopy in detecting vulnerable
plaques
The yellow color of the plaques is mainly caused by carotene which coexists with lipids in the vascular wall, and
therefore it is an indirect marker of vulnerability.
All prospective studies indicate that yellow plaques are
more prone to disruption than white plaques, but do not
indicate that all yellow plaques become disrupted.
22
Y. Uchida
Table 1 Histological classification of coronary plaques
based on distribution of lipids, calcium, collagen fibers, and
macrophage-foam cells.
Angioscopy
Histology
Superficial lipid deposition
group
CF-dense subtype
CF-loose subtype
CF-scanty subtype
Glistening yellow plaques
Non-glistening yellow
plaques
White plaques
Diffuse lipid deposition group
Non-NC type
CF-dense subtype
CF-loose subtype
CF-scanty subtype
NC type
Non-calcified cap type
CF-dense, CF-loose,
CF-scanty subtypes
Calcified cap type
CF-dense, CF-loose,
CF-scanty subtypes
Non-lipid deposition group
Regular subtype
Jelly-like subtype
Calcified cap subtype
The limited incidence of ACS in patients having yellow
plaques (even in high yellow plaque patients and multiple yellow plaque patients) suggests the existence of both
stable and vulnerable plaques in the yellow plaque group.
ACS developed, although at a lower incidence (4%), in
patients in whom white plaques but not yellow plaques were
detected. Furthermore, disrupted white coronary plaques
were observed in a prospective study [15]. This finding suggests the existence of vulnerable white plaques.
Coronary arteries are muscular arteries, and therefore
coronary arteries and the plaques therein are protected
against disruption by normal collagen fibers (CFs). During
plaque growth, CFs degenerate, are disrupted, and finally
destroyed.
Occlusive thrombosis occurs on the damaged (irrespective of erosion, ulcer, or lipid pool disruption) superficial
layers of the coronary plaques, and results in ACS. Therefore, demonstrating the lack of normal CFs together with
lipids and macrophages in the superficial layers of the
plaques is an essential requisite for the detection of vulnerable plaques. However, detailed examinations of the
relationships between angioscopic color images and the distribution of CFs are currently lacking.
In our study, white and yellow plaques were histologically classified into three and seven subtypes, respectively
(Table 1). CF-loose-to-scanty subtype of superficial lipid
deposition group, CF-loose-to-scanty cap subtype of lipid
pool (necrotic core) type, and calcified cap subtype of lipid
pool type in diffuse lipid deposition group of yellow plaques
were considered to be vulnerable. These subtypes exhibited
glistening yellow color, suggesting this color is a marker of
vulnerable plaques [25,26].
A vulnerable coronary plaque has a thin fibrous cap
with a large lipid core beneath: A fact or story?
A plaque having a thin fibroatheromatous cap with a large
lipid core beneath has been believed to be vulnerable. Based
on this hypothesis, intensive clinical studies have been carried out to investigate this type of plaque using IVUS and
OCT. However, ACS do not necessarily develop in patients
having a thin capped lipid core. Therefore, the thickness
of the cap was measured in a pathohistological study. However, there were no significant differences in cap thickness
among the CF-dense (histologically stable), CF-loose-toscanty (histologically vulnerable), and calcified cap subtypes
(histologically vulnerable), indicating that cap thickness did
not necessarily represent vulnerability [25].
Whether the hypothesis ‘‘the vulnerable plaque has a
thin fibrous cap with a large lipid core beneath’’ is a fact
or story should be settled.
Pre-stage of erosion
Plaque erosion is observed in around 25% of patients with
ACS, and sudden death not infrequently occurs in this group
of patients [27,28]. Although erosion can be detected by
angioscopy and OCT, what kind of images represents the prestage of erosion by these and other imaging tools had been
unclear. We conceived that jelly-like type in white plaque,
CF-scanty subtype of superficial lipid deposition group, and
calcified cap subtype of yellow plaques were a pre-stage of
erosion.
Acute coronary syndromes without obvious
coronary plaque disruption
There are patients with ACS in whom disrupted coronary
plaques are not detectable. Persistent coronary spasm or
accidental coronary thromboembolism has been proposed
as the causative mechanisms, however without definite evidence.
Fluffy (frosty glass-like) luminal surface of a non-stenotic
coronary segment was observed in a certain group of
patients with ACS (Fig. 3). The same luminal changes
were reproduced in animals when blood was perfused after
endothelial damages. Attachment of fibrin threads and
platelets on the damaged endothelial cells was detected by
histology, suggesting residual thrombus after autolysis. The
same mechanisms may participate in patients with ACS without significant coronary stenosis, or without demonstrable
plaque disruption. However, the genesis of endothelial damage remains to be elucidated [29]. Extensive endothelial cell
apoptosis induced through catecholamine--adrenoceptorcaspase pathway [30] may play a role in this phenomenon.
Detection of vulnerable coronary plaques by new
imaging modalities
Thus, limitation of conventional angioscopy using white light
in detecting vulnerable plaques became evident. Therefore,
the following imaging tools were developed for more objective diagnosis of vulnerable plaques.
Recent advances in coronary angioscopy
23
Figure 3 Fluffy coronary luminal surface. A 51-year-old female with unstable angina (UA). (A) Angiogram of the left coronary
artery. The middle segment of the left anterior descending artery observed by angioscopy is shown by the arrow. The margin of the
segment was irregular (arrow). (B) Angioscopic image of the same segment. The entire circumference of the luminal surface was
fluffy (diffuse type) and white (arrows). Arrowhead, guidewire. (C) The fluffy surface was diffusely stained blue with Evans blue
(arrow).
Reproduced from Uchida et al. [29] with permission.
Detection of vulnerable coronary plaques by
near-infrared spectroscopy
ing that the yellow-to-orange plaques were most vulnerable
[34] (Figs. 5 and 6).
Discrimination of cholesterol and cholesteryl esters in the
excised human plaques by near-infrared spectroscopy (NIRS)
in vitro was performed by Weinmann and Waxman [31,32].
This method is also applicable for detection of collagens,
low-density lipoprotein, etc. This method has a potential
use for molecular analysis of vulnerable plaques.
Evaluation of progressiveness toward vulnerable
plaques
Detection of vulnerable coronary plaques by
near-infrared fluorescence angioscopy
Two-dimensional imaging of cholesterol and cholesteryl
esters within human coronary plaques was accomplished by
near-infrared fluorescence angioscopy (NIRFA). The plaques
in human coronary plaques both in vitro and in vivo
were classified into NIRF absent, homogenous, doughnutshaped, and spotty types. Histological examinations showed
that these image patterns were determined mainly by carotene-conjugated cholesterol, cholesteryl esters, and
calcium, and the latter two types were considered vulnerable [33] (Fig. 4).
Detection of vulnerable coronary plaques by color
fluorescence angioscopy
Fluorescence of excised human coronary plaques was examined by color fluorescence angioscopy (CFA) using a 345 nm
band-pass filter (BPF) and a 420 nm band-absorption filter
(BAF).
Coronary plaques exhibited blue, green, white-to-light
blue, or yellow-to-orange fluorescence. Fluorescence microscopic studies revealed that collagen subtypes, cholesterol,
cholesteryl esters, calcium, and -carotene determine the
fluorescence color of the plaques. Histological examinations
revealed dense CFs without lipids in blue plaques; dense CFs
and lipids in green plaques; meager CFs and abundant lipids
in white-to-light blue plaques; and the absence of CFs and
deposition of lipids, calcium, and macrophage foam cells in
the thin fibrous cap in yellow-to-orange plaques, indicat-
Based upon the knowledge about the pathophysiology of
atherosclerosis, in vitro and in vivo and clinical trials have
been performed using different tracers for plaque imaging
studies, including radioactive-labeled lipoproteins, components of the coagulation system, cytokines, mediators of
the metalloproteinase system, cell adhesion receptors, and
even whole cells [26], or antibodies of the above-mentioned
substances.
Oxidized low-density lipoprotein imaging
Oxidized low-density lipoprotein (OxLDL) plays a key
role in the initiation, progression, and destabilization of
atherosclerotic plaques [35,36].
Therefore, if oxLDL is visualized in vivo, the fate (progressiveness) of plaques can be prospected and the effects
on them of medical and interventional therapies can be
more objectively evaluated.
In the presence of Evans blue dye, oxLDL exhibited violet
and brown fluorescence by exciting at 345 nm and emitted
at 420 nm (A-imaging) and by exciting at 470 nm and emitting at 515 nm (B-imaging), respectively. This combination
of fluorescence color was not observed in the other major
substances composing atherosclerotic plaques. This combination of fluorescence was observed not only in yellow but
also in white plaques of excised human coronary artery.
Moreover, fluorescence characteristics of oxLDL in the coronary plaques were successfully visualized in patients [34]
(Fig. 7).
Lysophosphatidylcholine imaging
Lysophosphatidylcholine (LPC) is a pro-inflammatory substance, and it is the major bioactive phospholipid
component of oxLDL and plays a critical role in the atherogenic activity of oxLDL [37].
The fluorescence characteristic of LPC in excised human
coronary plaques was investigated by color fluorescence
24
Y. Uchida
Figure 4 Relationships among conventional angioscopic, near-infrared fluorescence angioscopy (NIRFA), and near-infrared fluorescence microscopy (NIRFM) scanned images and histological changes in excised human coronary plaques. From A to D: the images
of coronary plaques by conventional angioscopy. From a to d: corresponding NIRFA images of the same plaques. From ␣ to ␦: corresponding NIRFM scanned images of the cut wall surface of the same specimens. From 1 to 4: corresponding histological images
after staining with Oil Red-O and methylene blue. Red and black portions indicate lipids and calcium, respectively. Horizontal bar
at the left upper corner of each panel: 100 m. A: a white plaque. From B to D: yellow plaques. a and b: homogenous type. Arrows:
homogenous near-infrared fluorescence (NIRF); c: doughnut-shaped type. Arrow: NIRF absent portion surrounded by strong NIRF
region; d: spotty type. Arrow: spots. ␣ and : homogenous NIRF (arrows); ␥: necrotic core lacking NIRF (arrow) surrounded by strong
NIRF region; ␦: fibrous cap with strong NIRF spots (arrow). 1: homogenous deposition of lipids deep in the plaque (arrow); 2: lipid
deposition in entire plaque; 3: lipid-deposited fibrous cap with a necrotic core (NC) below; 4: calcium particles distributed within
a lipid-laden fibrous cap. Red: lipids. Black: calcium compounds (arrow). Horizontal bar: 100 m.
Reproduced from Uchida et al. [39], with permission
angioscopy using Trypan blue dye (TB) as an indicator. In
the presence of TB, LPC exhibited a red fluorescence at Aand B-imaging. This red fluorescence at A- and B-imaging
was observed in human coronary plaques [38].
even by microscopy. Their imaging by angioscopy is still not
successful. By imaging cells and molecules, vulnerable
plaques can be characterized on a cellular or molecular
basis.
Cholesterol and cholesteryl ester imaging
Garg and Waxman succeeded in in vivo imaging of cholesterol and cholesteryl esters by spectroscopy [32]. The
present author succeeded in two-dimensional imaging of
cholesterol and cholesteryl esters within the coronary
plaques using NIRFA in patients [39] (Fig. 8).
Evaluation of stabilization and regression of
vulnerable plaques by angioscopy
Macrophage imaging
Macrophages play an important role in plaque progression.
Discrimination of macrophages and foam cells is difficult
Lipid-lowering therapy
Effects of lipid-lowering therapy using fibrates or statins on
coronary plaques were evaluated by several workers, and
reduction of yellow color grade was observed as shown in
Fig. 9 [13,40,41]. However, the changes in yellow plaque
color induced by these agents were different among the
plaques even in a given patient [13].
Recent advances in coronary angioscopy
25
Figure 5 Relationships between images produced by conventional angioscopy, color fluorescence angioscopy (CFA) and color fluorescence microscopy (CFM) scanning. From A to D: conventional angioscopic images of coronary plaques. From a to d: corresponding
CFA images using ‘‘A’’ imaging. From ␣ to ␦: corresponding CFM scanned images using ‘‘A’’ imaging. Horizontal bar: 100 m. A:
a white plaque observed during conventional angioscopy (arrow) exhibited blue fluorescence by CFA (arrow in a) and CFM scan
(␣). B: a yellow plaque observed during conventional angioscopy (arrow) exhibited green fluorescence seen during CFA (arrow in
b) and CFM scan (arrow in ). C: a yellow plaque observed during conventional angioscopy (arrow) exhibited white-to-light blue
fluorescence seen during CFA (c) and deposition of yellow substances in the white-to-light blue area (arrow in␥). D: a yellow plaque
observed during conventional angioscopy (arrow) exhibited yellow fluorescence observed during CFA (d) and deposition of orange
(white arrowhead), white (white arrow) and blue (yellow arrow) substances in the area of no fluorescence by CFM scanning.
Reproduced from Uchida et al. [34], with permission.
Molecular or cellular targeting therapy
Targeting therapy of oxLDL, metalloproteinases, or
macrophages may be a promising option for stabilization
and regression of vulnerable plaques. Although invasive,
fluorescence angioscopy may be a promising imaging modality for direct evaluation of molecular or cellular targeting
therapy of atherosclerotic plaques.
Evaluation of neointimal coverage of coronary
stents by angioscopy
Neointima formation on stent struts is essential for vascular wound healing process. Drug-eluting stents (DES) inhibit
the mobilization and differentiation of progenitor cells of
endothelial cells and smooth muscle cells, and thus not
only inhibit restenosis but also impair neointima formation,
which may lead to stent thrombosis.
DES have reduced restenosis significantly, but their shortcomings became evident, namely insufficient stent strut
coverage by neointima, and consequent late-stent thrombosis (LST) or very LST, and consequent ACS which can occur
on termination of anti-thrombotic therapy. This is a typical example of ‘‘a new therapeutic modality that has a new
complication’’.
Coronary angioscopy contributed greatly in clarifying
mechanisms of neointimal coverage of stent struts and LST
as follows:
Grading of neointimal coverage by angioscopy
The thickness of the neointima on the stent struts can be
assessed by angioscopy based on whether or not the stent
struts can be seen through the neointima.
Higo et al. and Oyabu et al. classified neointimal coverage
by angioscopy into: grade 0, not covered; grade 1, covered
by a thin layer; and grade 2, buried under neointima [42,43].
Difference in neointimal coverage between bare-metal
and drug-eluting stents
Although restenosis rates have been markedly reduced
by DES, it became evident that stent strut coverage by
neointima was incomplete or much delayed in cases of
DES when compared with bare-metal stents (BMS) [43—45].
It was also clarified that neointimal coverage is different
among DES [46].
Late-stent thrombosis
Fig. 10 shows an example of occlusive LST. LST occurs in both
BMS and DES. The prevalence was significantly higher in the
26
Y. Uchida
Figure 6 Lipids, calcium compounds, collagen fibers (CFs), and macrophage foam cells in the same plaques as those shown in
Fig. 5. From A to D: microscopic images after Oil-red O and methylene blue staining obtained from the same plaques in A to D in
Fig. 5, respectively. Red: lipids. Black: calcium. LC: lipid core. Horizontal bar: 100 m. From a to d: CFs stained by silver staining.
No normal CFs in d. Arrow in d: plaque debris. Horizontal bar: 20 m. From ␣ to ␦: images of ceramide in macrophage foam
cells obtained by ‘‘B’’ imaging of color fluorescence microscopy (CFM) after Ziel—Neelsen staining. Orange fluorescence (arrows):
macrophage foam cells. Arrowhead in ␥: residual collagen fibers (CFs). Horizontal bar: 20 m. A: a plaque without lipids, with
abundant normal CFs (a) and without macrophage foam cells (␣). B: a plaque with lipids, with thick CFs (b) but without macrophage
foam cells (). C: a plaque with lipid deposition and cavity formation, meager CFs (c) and disseminated macrophage foam cells
(arrow in ␥). D: a plaque with a thin fibrous cap with lipids and calcium (arrow in D), without CFs (d) and with multiple macrophage
foam cells (arrows in ␦).
Reproduced from Uchida et al. [34], with permission.
DES than that in BMS [47], probably due to the higher prevalence of neointimal coverage. Awata et al. observed that
LST was more frequently observed in sirolimus-eluting stents
(SES) than in paclitaxel-eluting stents (PES) (43% vs 19%) at
6 months [48]. They also reported that LST was observed in
31% of patients in the SES group versus 6% of patients in the
zotalorimus (ZES) group at 6 months.
Possible mechanisms of late-stent thrombosis and
appropriate neointimal thickening to prevent
restenosis, and neoendothelial cell damages and
consequent late-stent thrombosis
Endothelial cells are highly anti-thrombotic. The same may
also be true for neoendothelial cells regenerated after stent
implantation.
Neointima acts as a cushion between neoendothelial cells and the stent struts. If the neointima is thin,
stent struts are considered to be dislocated synchronizing to blood pressure changes and cardiac motion, and
accordingly induce mechanical stress on the neoendothelial
cells.
The struts were see-through (grade 0—1) by angioscopy
when the neointima thickness was below 130 m by OCT
in patients [49]. LST was observed in grade 0 or 1 group
in patients with DES or BMS [10,26,50]. At 6 months after
stenting, neoendothelial cells were stained in blue with
Evans blue dye which selectively stains damaged endothelial
cells when the neointima thickness grade was 0—1 [50,51]
(Fig. 11). In animals, the struts were visible (grade 0 or
1) when the neointimal thickness was around 88 m and
LST was frequently observed when the intimal thickness
was within 100 m [51]. All these findings indicated that
neoendothelial cells were damaged and LST formed on the
Recent advances in coronary angioscopy
27
Figure 7 Ox-LDL imaged by color fluorescence angioscopy (CFA) in the coronary artery in a patient with angina pectoris. Reddish
brown fluorescence observed in a non-stenotic proximal segment of the left anterior descending coronary artery after the intracoronary injection of EB in a patient with stable angina pectoris. A: an angiogram of the left coronary artery. Arrows a to b: the
proximal segment observed by CFA. The wall of the segment was uneven but significant stenosis was not found. From B to E: CFA
images of the same segment obtained after injecting EB, by advancing the angioscope distally from a to b of panel A. Reddish brown
portions indicate ox-LDL. The luminal surface was uneven, indicating early stage of atherosclerosis.
Reproduced from Uchida et al. [34] with permission.
Figure 8 Near-infrared fluorescence angioscopy (NIRFA) study in a 61-year-old male with stable angina. From A to C: angiogram,
conventional angioscopic image and NIRFA image of a plaque in the proximal segment of the left anterior descending coronary artery
(arrow in A). The yellow plaque (arrow in B) presented a homogenous type near-infrared fluorescence (NIRF) image (C). Arrowhead:
guide wire.
Reproduced from Uchida et al. [39], with permission.
Figure 9 Effects of oral administration of bezafibrate on coronary plaques. A: a yellow plaque before administration of bezafibrate
(arrow). B: the yellow plaque (arrow in A) disappeared 6 months later (arrow in B).
Reproduced from Uchida et al. [18] with permission.
28
Y. Uchida
Figure 10 An occlusive stent thrombus (late-stent thrombosis) formed 7 months after bare-metal stent (BMS) deployment. A
and B: A 57-year-old-male in whom ST-elevation myocardial infarction developed 7 months after BMS deployment. Arrow in A:
naked (grade 0) strut. Arrowheads: occlusive red thrombi. Arrow in B: struts and neighboring portions stained blue with Evans blue
indicating neoendothelial cell (NEC) damage and/or fibrin. Arrowheads correspond to those in A.
Figure 11 Staining of neoendothelial cells (NECs) 6 months after bare-metal stent (BMS) deployment. Neointimal coverage was
grade 1 because the struts were seen through (arrows in A). The struts were stained with Evans blue, indicating neoendothelial cell
(NEC) (arrows in B) damage.
struts when neointimal thickness was within approximately
100 m.
Determining exactly how to terminate this ‘‘vicious
cycle’’ is an essential requisite for effective prophylactic
treatment of LST.
Based on the angioscopic results in these clinical and animal studies, the control of neointimal regeneration over
100 m and below an appropriate thickness that does not
cause significant restenosis is an essential requisite for the
prevention of LST and restenosis.
Conclusion
Dark and glistening yellow coronary plaques observed
by conventional angioscopy using visual light have been
believed to be vulnerable based on the studies in patients
with ACS, histological examinations, and on prospective
studies. Further, the patients having multiple yellow plaques
have been believed more prone to suffer from ACS. Why
the patients having yellow plaques do not necessarily suffer from ACS is a recently raised question. Based on lipids,
collagen fibers, and calcium distribution patterns, yellow
coronary plaques are classified by histology into 7 stable
or vulnerable subgroups and conventional angioscopy can
not discriminate them. Recently, new imaging modalities
were developed to discriminate the substances or cells
that constitute the atherosclerotic plaques, namely nearinfrared spectroscopy and fluorescence angioscopy and so
on. Employing these imaging modalities, more specific identification of vulnerable plaques can be attained.
DES reduce coronary restenosis significantly, however,
LST occurs, which requires long-term antiplatelet therapy.
Angioscopic grading of neointimal coverage of coronary
stent struts has been established, and it was revealed that
neointimal formation is incomplete and prevalence of LST is
higher in DES when compared to BMS. It was also observed
that the neointima is thicker and LST is less frequent in PES
and ZES than in SES.
Endothelial cells are highly anti-thrombotic. Clinical and
animal studies have revealed that neoendothelial cells on
stent struts are damaged when the neointima is less than
100 m thick, and LST frequently occurs. In addition to toxic
effect of drugs or polymers of DES, neoendothelial cell damage is considered to be caused by friction between the cells
and stent struts due to the thin neointima between them
Recent advances in coronary angioscopy
which might act as a cushion. Therefore, it is conceivable
that to control neointimal regeneration over 100 m and
below appropriate thickness which does not cause significant
restenosis is necessary to prevent LST.
References
[1] Allen DS, Graham EA. Intracardiac surgery: a new method. Am
Med Assoc 1922;79:1028.
[2] Uchida Y, Tomaru T, Sumino S, Kato S, Sugimoto T. Fiberoptic
observation of thrombosis and thrombolysis in isolated human
coronary artery. Am Heart J 1986;112:694—6.
[3] Spears JR, Spokojny AM, Marais HJ. Coronary angioscopy during
cardiac catheterization. J Am Coll Cardiol 1985;6:93—7.
[4] Litvack F, Grundfest WS, Lee ME. Angioscopic visualization
of blood vessel interior in animals and humans. Clin Cardiol
1985;8:65—70.
[5] Uchida Y, Nakamura F, Tomaru T, Furuse A, Fujimori Y,
Hasegawa K. Percutaneous coronary angioscopy in patients
with ischemic heart disease. Am Heart J 1987;114:1216—22.
[6] Hoeler M, Homback V, Hoepp HW. Percutaneous coronary
angioscopy during cardiac catheterization. J Am Coll Cardiol
1988;11(65A) [abstract].
[7] Uchida Y, Tomaru T, Sugimoto T. Angioscopic observation of
coronary luminal changes induced by PTCA. Proc Jpn Coll Angiol
1984;85 [abstract].
[8] Uchida Y, Hasegawa K, Kawamura K, Shibuya I. Angioscopic
observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J
1989;117:769—76.
[9] Nakamura F, Kvasnicka J, Uchida Y, Geschwind HJ. Percutaneous angioscopic evaluation of luminal changes induced by
excimer laser angioplasty. Am Heart J 1992;124:1467—72.
[10] Ueda Y, Nanto S, Komamura K, Kodama K. Neointimal coverage
of stents in human coronary arteries observed by angioscopy. J
Am Coll Cardiol 1994;23:341—6.
[11] Ishikawa H, Uchida Y. Angioscopic features of coronary artery in
Kawasaki disease. In: Proceedings of 4th international Kawasaki
disease conference. 1991. p. 20—2.
[12] Sherman CT, Litvak F, Grandest W, Lee M, Hickey A, Chaux
R, Blanche C, Matloff J, Morgenstern L. Coronary angioscopy
in patients with unstable angina pectoris. New Engl J Med
1986;315:913—9.
[13] Uchida Y, Fujimori Y, Ohsawa H, Noike H. Angioscopic evaluation of the stabilizing effects of bezafibrate on coronary
plaques. Coronary 1997;16:293—301.
[14] Uchida Y, Tomaru T, Sugimoto T. Angioscopic observation of
coronary luminal changes induced by PTCA. Proc Jpn Coll Angiol
1984;50 [abstract].
[15] Uchida Y, Nakamura F, Tomaru T, Oshima T, Sasaki T, Morizuki
S, Hirose J. Prediction of acute coronary syndromes by percutaneous coronary angioscopy in patients with stable angina
pectoris. Am Heart J 1995;130:195—203.
[16] Uchida Y. Coronary angioscopy. Futura: Armonk, NY; 2001. p.
79—100.
[17] Ueda Y, Ohtani T, Shimizu M, Hirayama A, Kodama K. Assessment of plaque vulnerability by angioscopic classification of
plaque color. Am Heart J 2004;148:333—5.
[18] Uchida Y, Fujimori Y, Ohsawa H, et al. Angioscopic evaluation of stabilizing effects of bezafibrate on coronary plaques
in patients with coronary artery disease. Diag Therap Endosc
2000;7:21—8.
[19] Ishibashi F, Mizuno K, Kawamura A, Shin PP, Nesto RW, Waxman
S. High yellow color intensity by angioscopy with quantitative colorimetry to identify high-risk features in culprit lesions
of patients with acute coronary syndromes. Am J Cardiol
2007;100:1207—11.
29
[20] Okada K, Ueda Y, Oyabu J, Ogasawara N, Hirayama A, Kodama
K. Plaque color analysis by the conventional yellow-color grading system and quantitative measurement using LCH color
space. J Interv Cardiol 2007;20:324—34.
[21] Uchida Y, Egami H. What determines depth of yellow color
of coronary plaques. Proceedings of 20th annual meeting of
Japanese Association of Cardioangioscopy 2005:15.
[22] Ohtani T, Ueda Y, Mizoe I, Oyabu J, Okada K, Hirayama A,
Kodama K. Number of yellow plaques detected in a coronary
artery is associated with future risk of acute coronary syndrome: detection of vulnerable patients by angioscopy. J Am
Coll Cardiol 2006;47:2194—200.
[23] Takano M, Jang IK, Inami S, Yamamoto M, Murakami D, Komatsu
K, Seimiya K, Ohba T, Mizuno K. In vivo comparison of optical
coherence tomography and angioscopy for the evaluation of
coronary plaque characteristics. Am J Cardiol 2008;101:471—6.
[24] Komatsu S, Ueda Y, Omori Y, Kodama K. Diagnosis of vulnerable plaque and vulnerable patients by coronary angioscopy
and multi-detector row computed tomography (MCDCT)-from
invasive to non-invasive plaque imaging. Vasc Dis Preven
2006;3:319—25.
[25] Uchida Y, Egami H, Kameda N. Pitfalls of angioscopy in detecting vulnerable coronary plaques. Circ J 2010;74:273.
[26] Uchida Y. Angioscopic detection of vulnerable coronary
plaques. Curr Cardiovasc Imag Rep 2010;3:222—9.
[27] Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull
Jr W, Rosenfeld ME, Schwarz CJ, Wagner WD, Wissler RW. A
definition of advanced types of atherosclerotic lesions and a
histological classification of atherosclerosis: a report from the
committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 1995;92:1355—
74.
[28] Tavora F, Cresswell N, Li L, Ripple M, Fowler D, Burke A.
Sudden coronary death caused by pathologic intimal thickening without atheromatous plaque formation. Cardiovasc Pathol
2009;26:55—61.
[29] Uchida Y, Uchida Y, Sakurai T, Kanai M, Shirai S, Oshima T,
Tabata T. Fluffy luminal surface of the non-stenotic culprit
coronary artery in patients with acute coronary syndrome. Circ
J 2010;74:2379—85.
[30] Romeo F, Li D, Shi M, Mehta JL. Carvedilol prevents
epinephrine-induced apoptosis in human coronary artery
endothelial cell: modulation of Fas/Fas ligand and caspase-3
pathway. Cardiovasc Res 2000;45:788—94.
[31] Weinmann P, Jouan M, Nguyen QD, Lacroix B, Groiselle C, Bonte
JP, Luc G. Quantitative analysis of cholesterol and cholesteryl
esters in human atherosclerotic plaques using near-infrared
Raman spectroscopy. Atherosclerosis 1998;140:81—8.
[32] Garg R, Waxman S. Catheter-based near-infrared spectroscopy
for imaging of lipid-rich plaques. Curr Cardiovasc Imaging Rep
2010;3:403—11.
[33] Uchida Y, Noike H, Tomaru T, Kanai M, Sakurai T. Twodimensional imaging of lipids deposited in the coronary
plaques by near-infrared fluorescence angioscopy. Circulation
2007;118(Suppl. II):617.
[34] Uchida Y, Uchida Y, Kawai S, Kanamaru R, Sugiyama Y, Tomaru
T, Maezawa Y, Kameda N. Detection of vulnerable coronary
plaques by color fluorescent angioscopy. JACC Cardiovasc Imaging 2010;3:398—408.
[35] Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestd L, Oie
E, Aukrust P. Atherosclerotic plaque stability—–what determines
the fate of plaque? Prog Cardiovasc Dis 2008;51:183—94.
[36] Shah PK. Inflammation and plaque vulnerability. Cardiovasc
Drugs Ther 2009;23:31—40.
[37] Aiyar N, Disa J, Ao Z, Ju H, Nerurkar S, Willette RN, Macphee
CH, Johns DG, Dougla SA. Lysophosphatidylcholine induces
inflammatory activation of human coronary artery smooth muscle cells. Mol Cell Biochem 2007;295:113—20.
30
[38] Uchida Y, Uchida Y, Kawai S, Kanamaru R, Kameda N. Imaging
of lysophophatidylcholine in human coronary plaques by color
fluorescence angioscopy. Int Heart J 2010;51:129—33.
[39] Uchida Y, Uchida Y, Sugiyama Y, Kanai M, Sakurai T, Shirai S.
Two-dimensional visualization of cholesterol and cholesteryl
esters within human coronary plaques by near-infrared fluorescent angioscopy. Clin Cardiol 2010;33:322—5.
[40] Takano M, Mizuno K, Yokoyama S, et al. Changes in coronary
plaque color and morphology by lipid-lowering therapy with
atorvastatin: serial evaluation by coronary angioscopy. J Am
Coll Cardiol 2003;42:680—6.
[41] Hirayama A, Saito S, Ueda N, Takayama T, Honye J, Komatsu
S. Effects of strong statin on the stabilization and regression of coronary plaques as evaluated by coronary angioscopy
and intravascular ultrasound in Japanese subjects-TWINS and
TOGETHAR study. Circ J 2010;73:718—25.
[42] Higo T, Ueda Y, Oyabu J, Okada K, Nishio M, Hirata A, Kashiwase K, Ogasawara N, Hirotani S, Kodama K. Atherosclerotic
and thrombogenic neointima formed over SES. JACC Cardiovasc
Imaging 2009;2:616—24.
[43] Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama
K. Angioscopic evaluation of neointimal coverage: sirolimus
drug-eluting stent versus bare metal stent. Am Heart J
2006;52:1168—74.
[44] Sakai S, Mizuno K, Yokoyama S, Tanabe J, Shinada T, Seimiya
K, Takano M, Ohba T, Tomimura M, Uemura R, Imaizumi T. Morphologic changes in infarct-related plaque after coronary stent
placement. J Am Coll Cardiol 2003;42:1558—65.
Y. Uchida
[45] Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi
T, Iida O, Sera F, Nanto S, Hori M, Nagata S. Serial angioscopic
evidence of incomplete neointimal coverage after SES implantation. Circulation 2007;116:910—6.
[46] Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi
T, Sera F, Kotani J, Hori M, Nagata S. Angioscopic comparison
of neointimal coverage between zotarolimus- and sirolimuseluting stents. J Am Coll Cardiol 2008;52:789—90.
[47] Takano M, Ohba T, Inami S, Seimiya K, Sakai S, Mizuno K.
Angioscopic differences in neoinitmal coverage and in persistence of thrombus between sirolimus-eluting stents and
bare-metal stents after 6-month implantation. Eur Heart J
2006;27:2189—95.
[48] Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onish
T, Iida O, Sera F, Minamiguchi H, Kotani J, Nagata S. Heterogeneous arterial healing in patients following paclitaxel-eluting
stent implantation. J Am Coll Cardiol Interv 2009;2:453—8.
[49] Tsujimoto T. Relationships between angioscopic images of
coronary stents and neointimal thickness measured by OCT.
Proceedings of the 20th annual meeting of the Japanese Cardioangioscopy Society 2006:30.
[50] Uchida Y, Uchida Y, Fujimori Y. Endothelial cells covering coronary stents are frequently damaged. Circulation
2006;114(Suppl. II):591.
[51] Uchida Y, Uchida Y, Sakurai T, Kanai M. Possible role of damaged neo-endothelial cells in the genesis of coronary stent
thrombosis: a dye-staining angioscopic study. Int Heart J
2010;51:700—6.